Adaptive Biotech Q2 Revenue Jumps 22%, Beats Estimates; Raises MRD Outlook
ADPT has more than doubled off its 52-week low of $9.955.
Summary
Adaptive Biotechnologies delivered a strong Q2, with revenue rising 22% to $71.55M, beating the $65.89M consensus. The MRD business drove the beat—revenue there surged 33% and now makes up 92% of total revenue, while clonoSEQ test volume jumped 43% to over 36,000 tests. Adjusted EBITDA loss narrowed to just -$726K, far better than the -$4.32M expected. Management raised full-year MRD revenue guidance to $268M-$278M and trimmed operating expense guidance to $350M-$355M, signaling confidence in the core diagnostic franchise. The company also announced plans to separate the declining Immune Medicine unit, which fell 40% in the quarter. This follows a $345M convertible note issuance in June and a strategic review of the Immune Medicine business, suggesting a sharper focus on the high-growth MRD segment. With the stock trading near its 52-week high, the raised guidance and operational leverage could support further upside.
At the time of this announcement, ADPT was trading at $22.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $9.96 to $23.15. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.